AAPL   263.17 (-3.78%)
FB   187.24 (-1.32%)
MSFT   157.13 (-0.66%)
GOOGL   1,277.70 (-2.83%)
AMZN   1,841.11 (-2.29%)
NVDA   253.94 (+0.53%)
TSLA   632.73 (-6.81%)
AMD   42.80 (-2.75%)
T   34.42 (-3.67%)
F   6.75 (-3.16%)
BAC   27.93 (-4.12%)
DIS   114.54 (-2.97%)
AAPL   263.17 (-3.78%)
FB   187.24 (-1.32%)
MSFT   157.13 (-0.66%)
GOOGL   1,277.70 (-2.83%)
AMZN   1,841.11 (-2.29%)
NVDA   253.94 (+0.53%)
TSLA   632.73 (-6.81%)
AMD   42.80 (-2.75%)
T   34.42 (-3.67%)
F   6.75 (-3.16%)
BAC   27.93 (-4.12%)
DIS   114.54 (-2.97%)
AAPL   263.17 (-3.78%)
FB   187.24 (-1.32%)
MSFT   157.13 (-0.66%)
GOOGL   1,277.70 (-2.83%)
AMZN   1,841.11 (-2.29%)
NVDA   253.94 (+0.53%)
TSLA   632.73 (-6.81%)
AMD   42.80 (-2.75%)
T   34.42 (-3.67%)
F   6.75 (-3.16%)
BAC   27.93 (-4.12%)
DIS   114.54 (-2.97%)
AAPL   263.17 (-3.78%)
FB   187.24 (-1.32%)
MSFT   157.13 (-0.66%)
GOOGL   1,277.70 (-2.83%)
AMZN   1,841.11 (-2.29%)
NVDA   253.94 (+0.53%)
TSLA   632.73 (-6.81%)
AMD   42.80 (-2.75%)
T   34.42 (-3.67%)
F   6.75 (-3.16%)
BAC   27.93 (-4.12%)
DIS   114.54 (-2.97%)
Log in

NASDAQ:MRUS - Merus Stock Price, Forecast & News

$16.74
+0.30 (+1.82 %)
(As of 02/28/2020 10:38 AM ET)
Today's Range
$16.74
Now: $16.74
$16.74
50-Day Range
$14.48
MA: $17.18
$19.44
52-Week Range
$11.42
Now: $16.74
$20.95
Volume7 shs
Average Volume53,414 shs
Market Capitalization$391.88 million
P/E RatioN/A
Dividend YieldN/A
Beta0.1
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRUS
CUSIPN/A
Phone31-0-30-253-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$37.14 million
Book Value$4.77 per share

Profitability

Net Income$-28,660,000.00

Miscellaneous

Employees98
Market Cap$391.88 million
Next Earnings Date4/1/2020 (Estimated)
OptionableNot Optionable

Receive MRUS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter.


Merus (NASDAQ:MRUS) Frequently Asked Questions

What is Merus' stock symbol?

Merus trades on the NASDAQ under the ticker symbol "MRUS."

When is Merus' next earnings date?

Merus is scheduled to release their next quarterly earnings announcement on Wednesday, April 1st 2020. View Earnings Estimates for Merus.

What price target have analysts set for MRUS?

6 brokers have issued 1-year price targets for Merus' shares. Their forecasts range from $16.00 to $35.00. On average, they anticipate Merus' share price to reach $24.00 in the next twelve months. This suggests a possible upside of 43.4% from the stock's current price. View Analyst Price Targets for Merus.

What is the consensus analysts' recommendation for Merus?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merus.

Has Merus been receiving favorable news coverage?

Headlines about MRUS stock have been trending extremely negative on Friday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Merus earned a daily sentiment score of -4.4 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Merus.

Are investors shorting Merus?

Merus saw a decrease in short interest in the month of February. As of February 14th, there was short interest totalling 368,500 shares, a decrease of 15.6% from the January 30th total of 436,600 shares. Based on an average trading volume of 76,600 shares, the short-interest ratio is currently 4.8 days. Approximately 2.0% of the company's shares are sold short. View Merus' Current Options Chain.

Who are some of Merus' key competitors?

What other stocks do shareholders of Merus own?

Who are Merus' key executives?

Merus' management team includes the folowing people:
  • Dr. Ton Logtenberg, Pres, CEO, Principal Financial Officer & Exec. Director (Age 61)
  • Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific Advisor
  • Ms. Jillian Connell, VP of Investor Relations & Corp. Communications
  • Mr. John de Kruif Ph.D., CTO & Sr. VP (Age 55)
  • Mr. Mark Throsby Ph.D., Chief Scientific Officer & Exec. VP (Age 52)

When did Merus IPO?

(MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Who are Merus' major shareholders?

Merus' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (13.54%), EcoR1 Capital LLC (7.34%), Driehaus Capital Management LLC (6.13%), Platinum Investment Management Ltd. (0.73%), Oxford Asset Management LLP (0.22%) and Old West Investment Management LLC (0.11%). Company insiders that own Merus stock include Bvf Partners L P/Il, Mark Throsby and Value Fund L P Biotechnology. View Institutional Ownership Trends for Merus.

Which major investors are selling Merus stock?

MRUS stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL and Tower Research Capital LLC TRC . View Insider Buying and Selling for Merus.

Which major investors are buying Merus stock?

MRUS stock was acquired by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Driehaus Capital Management LLC, Oxford Asset Management LLP, Platinum Investment Management Ltd., Old West Investment Management LLC, Renaissance Technologies LLC, Marshall Wace LLP and Acadian Asset Management LLC. Company insiders that have bought Merus stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for Merus.

How do I buy shares of Merus?

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Merus' stock price today?

One share of MRUS stock can currently be purchased for approximately $16.74.

How big of a company is Merus?

Merus has a market capitalization of $391.88 million and generates $37.14 million in revenue each year. The biotechnology company earns $-28,660,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Merus employs 98 workers across the globe.View Additional Information About Merus.

What is Merus' official website?

The official website for Merus is http://www.merus.nl/.

How can I contact Merus?

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]


MarketBeat Community Rating for Merus (NASDAQ MRUS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  254 (Vote Outperform)
Underperform Votes:  254 (Vote Underperform)
Total Votes:  508
MarketBeat's community ratings are surveys of what our community members think about Merus and other stocks. Vote "Outperform" if you believe MRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: Treasury Bonds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel